Influenza, Human  >>  Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
NCT00551629: A Study to Test the Safety and Effectiveness of an Investigational Vaccine in Infants (V419-002)

Completed
2
708
Canada
AR51 (12, 10), PR51 (3, 10), PR51 (6, 10), PR51 (6, 15)
Merck Sharp & Dohme LLC
Bacterial Infections; Virus Diseases
03/03
03/03
NCT00362427: Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®

Completed
2
460
Canada
Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC, PR5I, PENTACEL™, NGERIX-B®
Sanofi Pasteur, a Sanofi Company, Merck Sharp & Dohme LLC
Diphtheria, Pertussis, Polio, Hepatitis B, Tetanus
02/09
03/09

Download Options